Pharmacokinetics and pharmacodynamics of Ro 44-3888 after single ascending oral doses of sibrafiban, an oral platelet aggregation inhibitor, in healthy male volunteers

British Journal of Clinical Pharmacology

Volumn 47, Issue 5, 1999, Pages 521-530

  Wittke, Bärbel ^a,b   Mackie, Ian J ^a   Machin, Samuel J ^a   Timm, Uwe ^b   Zell, Manfred ^c   Goggin, Timothy ^b  

^a Department of Clinical Pharmacology   (Brazil)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

^c UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

Oral platelet inhibitor; Pharmacodynamics; Pharmacokinetics; Ro 44 3888; Sibrafiban

Indexed keywords

ANTITHROMBOCYTIC AGENT; FIBRINOGEN RECEPTOR; RO 44 3888; SIBRAFIBAN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION INHIBITION;

ADENOSINE DIPHOSPHATE; ADMINISTRATION, ORAL; ADULT; AMIDINES; AREA UNDER CURVE; CONTUSIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; OXIMES; PEPTIDE FRAGMENTS; PIPERIDINES; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PRODRUGS; RECEPTORS, THROMBIN;

EID: 0032932924     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1999.00931.x     Document Type: Article

References (12)

1. Haas WK, Easton JD, Adams HP, et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501-507.
2. Vane Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature New Biol 1971; 231: 232-235.
3. Schrör K. The basic pharmacology of ticlopidine and clopidogrel. Platelets 1993, 4: 252-261.
4. Pytcla R, Pierschbacher MD, Ginsberg MH, et al. Platelet membrane glycoprotcin Ilb/IIa: member of a family of ArgGly-Asp-specific adhesion receptors. Science 1986; 231: 1559-1562.
5. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotcin Ilb-IIIa receptor in high-risk coronary angioplasty. N EiiglJ Mcd 1994; 330: 956-1007.
6. Timm U, Zumbrunncn R, Erdin R, Singer M, Steiner B. Oral platelet aggregation inhibitor Ro 48-3657. Determination of the active metabolite and its prodrug in plasma and urine by high-performance liquid chromatography using automated column switching. J Chromatog B 1997; 691: 397-407.
7. Zcll M, Husser C, Hopfgartner G. Column-switching high-performance liquid chromatography combined with ionspray tandem mass spectrometry for the simultaneous determination of the platelet inhibitor Ro 44-3888 and its pro-drug and precursor metabolite in plasma. J Mass Spec 1997; 32: 23-32.
8. Gibaldi M, Perrier D. Pliartnacokinctics. Marcel Dekker, New York, 1982.
9. SAS Institute Inc., SAS Campus Drive, Cary, NC 27513, 1990.
10. Investigational Drug Brochure. F. Hoffmann-La Roche Ltd., CH-Basel, 1997.
11. NONMEM Project Group, C255, University of California at San Francisco, San Francisco, CA 94143.
12. Funk Ch., F. Hoffmann-La Roche Ltd., CH-Basel, personal communication, data on file.